Compare PRAX & CFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | CFLT |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.7B |
| IPO Year | 2020 | 2021 |
| Metric | PRAX | CFLT |
|---|---|---|
| Price | $309.41 | $30.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 28 |
| Target Price | ★ $572.13 | $28.73 |
| AVG Volume (30 Days) | 328.9K | ★ 7.9M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.63 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,166,748,000.00 |
| Revenue This Year | N/A | $18.71 |
| Revenue Next Year | $6,395.88 | $16.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.08 |
| 52 Week Low | $26.70 | $15.64 |
| 52 Week High | $354.87 | $30.81 |
| Indicator | PRAX | CFLT |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 61.56 |
| Support Level | $290.36 | $30.60 |
| Resistance Level | $322.32 | $30.79 |
| Average True Range (ATR) | 16.44 | 0.07 |
| MACD | -4.21 | -0.03 |
| Stochastic Oscillator | 38.39 | 53.49 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.